Trial Profile

A confirmatory study of pridopidine in early HD patients.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 29 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Oct 2025 New trial record
10 Oct 2025 According to a Prilenia Therapeutics media release, Prilenia and Ferrer plan to initiate a global confirmatory study of pridopidine in early-stage HD patients not taking ADMs - expected to commence in the first half of 2026. In addition to the primary population, a small, proof-of-concept arm of patients taking low-dose ADMs (per label guidance) is also planned to be enrolled.
05 Sep 2025 According to a Prilenia Therapeutics media release, A planned confirmatory study in early HD patients, designed to confirm pridopidines effects and support global regulatory approval pathway discussions, is expected to start next year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com